Initially, infusion of apoA-I Milano, a naturally occurring mutation of apoA-I associated with low prevalence of CVD [32,33], showed regression of coronary atherosclerosis in a phase II trial (“The ApoA-I Milano Trial”) [34]. This evidence concerns the gene APOA1 and coronary atherosclerosis.